Andrea Wolf, MD, on Lung Cancer Rates in Women

Video

The director of the new Women’s Lung Cancer Program at Mount Sinai spoke about the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

According to recent studies, more women have died of lung cancer than the total number of women who have died from breast, ovarian and uterine cancer combined.

Moreover, women who have never smoked are suggested to be twice as likely to develop lung cancer than men who have never smoked, partially due to genetic and other factors. Women who smoke are also more likely to develop lung cancer than men, and when screened, women are almost twice as likely to be diagnosed with lung cancer.

Given these staggering statistics, Andrea Wolf, MD, and her colleagues at Mount Sinai launched the Women’s Lung Cancer Program in an attempt to address these issues in both research and screening. In an interview with CancerNetwork®, Wolf, director of the new Women’s Lung Cancer Program, discussed the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Related Content